Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin

Journal of Cutaneous Pathology

Volumn 30, Issue 9, 2003, Pages 591-595

  English III, Joseph C ^a   Toney, Rachel ^b   Patterson, James W ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN DERIVATIVE; LIPOSOME;

ADENOCARCINOMA; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DERMATITIS; DISEASE COURSE; DRUG DELIVERY SYSTEM; FEMALE; HISTOPATHOLOGY; HUMAN; MEDICAL EXAMINATION; PUNCH BIOPSY; SKIN TOXICITY; TISSUE SECTION; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTIBIOTICS, ANTINEOPLASTIC; BIOPSY; DIAGNOSIS, DIFFERENTIAL; DOXORUBICIN; FEMALE; GRAFT VS HOST DISEASE; HUMANS; INTERTRIGO; KERATINOCYTES; LIPOSOMES; MIDDLE AGED; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS;

EID: 0141958783     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0560.2003.00113.x     Document Type: Article

References (21)

1. Waterhouse DN, Tardi PG, Mayer LD, et al. A comparison of liposomal formulations of doxorubicin with drug administration in free form; changing toxicity profiles. Drug Saf 2001; 24 (12): 903.
2. Woessner R, An Z, Xioming L, et al. Comparison of three approaches to doxorubicin therapy: free doxorubicin, liposomal doxorubicin and B-glucuronidase-activated prodrug (HMR 1826). Anticancer Res 2000; 20: 2289.
3. Torti FM, Bristow MR, Howes AE, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule; assessment by endomyocardial biopsy. Ann Intern Med 1983; 99: 745.
4. Muggia FM. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs 1997; 54 (Suppl. 4): 22.
5. Skelton H, Linstrum J, Smith K. Host-vs.-altered-host eruptions in patients on liposomal doxorubicin. J Cutan Pathol 2002; 29: 148.
6. Molineux G. Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat Rev 2002; 28 (Suppl. A): 13.
7. Yowell SL, Blackwell S. Novel effects with polyethylene glycol modified pharmaceuticals. Cancer Treat Rev 2002; 28 (Suppl. A): 3.
8. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001; 19 (4): 424.
9. Goram AL, Richmond PL. Pegylated liposomal doxorubicin: tolerability and toxicity. Pharmacotherapy 2001; 21 (6): 751.
10. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999; 40: 367.
11. Lotem M, Hubert A, Lyass O, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 2000; 136: 1475.
12. Alberts DS, Garcia DJ. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997; 54 (Suppl.4): 30.
13. Lopez AM, Wallace L, Dorr RT, et al. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol 1999; 44: 3003.
14. Henry LB, Horn TD. Chemotherapy and keratinocytes. J Cutan Pathol 2002; 29: 575.
15. Castano E, Rodriquez-Peralto JL, Lopez-Rios F, et al. Keratinocyte dysplasia: an unusual finding after transplantation or chemotherapy. J Cutan Pathol 2002; 29: 579.
16. Fitzpatrick JE, Hood AF. Histopathologic reactions to chemotherapeutic agents. Adv Dermatol 1988; 3: 161.
17. Horn TD. Acute cutaneous eruption after marrow ablation: roses by other names? J Cutan Pathol 1994; 21: 385.
18. Hiroki A, Nakamura S, Shinohara M, et al. Significance of oral examination in chronic graft-versus-host disease. J Oral Pathol Med 1994; 23: 209.
19. Nicolatou-Galitis O, Kitra V, Van-Constantinidou C, et al. The oral manifestations of chronic graft-versus-host disease (cGVHD) in paediatric allogenic bone marrow transplant recipients. J Oral Pathol Med 2001; 30: 148.
20. Morelli D, Menard S, Colnaghi MI, et al. Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice. Cancer Res 1996; 56: 2082.
21. Zhang J, Clark JR Jr., Herman EH, et al. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine and inhibition by ICRF-187. J Mol Cell Cardiol 1996; 28: 1931.